ASTRAZENECA

AstraZeneca on Thursday detailed its plan to invest $50 billion in the U.S. by 2030 and an agreement with the government to lower some drug prices, as it reported a 10% rise in revenue for the first nine months of the year.

AstraZeneca shareholders have approved a plan to unify the company's share listing structure across London, Stockholm, and New York.

AstraZeneca PLC and Amgen Inc. said Wednesday their drug Tezspire has been approved in the European Union to treat a chronic inflammatory nasal condition.

AstraZeneca and Amgen said Monday their drug Tezspire has been approved in the U.S. as a treatment for a chronic inflammatory nasal condition.

AstraZeneca's lupus drug Saphnelo has been recommended for approval in the European Union in a new, more convenient self-administered form.

AstraZeneca PLC has reached an agreement with the U.S. government to lower the cost of some prescription medicines for American patients and significantly boost its domestic manufacturing.